About this Activity
This program will provide clinicians with a thorough understanding of the consequences and quality-of-life implications of daytime sleepiness, as well as updated information on the pharmacology and risks and benefits of currently available and emerging agents used in the treatment of insomnia.

Learning Objectives
By participating in this symposium, learners will be able to:

• Describe the impact of insomnia including the relationship between primary insomnia and daytime function
  
• Outline the pharmacology of medications used in the management of chronic insomnia
  
• Compare and contrast the efficacy and safety of current and emerging agents used in the treatment of insomnia

Who Will Benefit
This activity was designed to meet the continuing education needs of psychiatrists and other physicians. Other mental health professionals may find this activity informative and should check with their state licensing and certification boards to determine if it meets their continuing education requirements.

Your Distinguished Faculty

	Gary K. Zammit, PhD Director, Sleep Disorders Institute; Clinical Associate Professor of Psychology in Psychiatry, Columbia University College of Physicians and Surgeons
	Thomas Roth, PhD Director, Sleep Disorders and Research Center, Henry Ford Hospital; Clinical Professor, Department of Psychiatry, University of Michigan; Chief, Sleep Medicine, Henry Ford Hospital

Faculty Disclosures
Gary K. Zammit, PhD, has received grants and research support from Ancile Pharmaceuticals, Inc., Aventis Pharmaceuticals, Cephalon, Inc., Elan Pharmaceuticals, Inc., Forest Pharmaceuticals, Inc., GlaxoSmithKline, H. Lundbeck A/S, King Pharmaceuticals, Merck and Co., Inc., Neurocrine Biosciences, Inc., Organon Pharmaceuticals USA, Inc., Orphan Medical, Pfizer Inc., Sanofi-Synthelabo Inc., Sepracor, Takeda Pharmaceuticals North America, UCB Pharma Inc. and Wyeth-Ayerst Research. He serves as a consultant for Aventis Pharmaceuticals, Cephalon, Inc., Elan Pharmaceuticals, Inc., GlaxoSmithKline, King Pharmaceuticals, Merck and Co., Inc., Neurocrine Biosciences, Inc., Organon Pharmaceuticals USA, Inc., Pfizer Inc., Sepracor and Takeda Pharmaceuticals North America. He has received honoraria from Neurocrine Biosciences, Inc., King Pharmaceuticals, McNeil Consumer & Specialty Pharm., Sanofi-Synthelabo Inc., Takeda Pharmaceuticals North America, Vela Pharmaceuticals and Wyeth-Ayerst Research.

Thomas Roth, PhD, is a member of the Speakers Bureau for Sanofi-Synthelabo Inc., Takeda Pharmaceuticals, and Cephalon, Inc. He receives grant research support from Aventis, Cephalon, Inc., GlaxoSmithKline, SchoeringPlough, Somaxon, Syrex, Wyeth, Xenoport, TransOral Pharmaceutical, Inc., Neurocrine Biosciences, Inc., Sanofi-Synthelabo Inc., Pfizer Inc., Takeda Pharmaceuticals North America and Sepracor. He also serves as a consultant for Accadia, Acoglix, Alchemers, Alza, Ancil, AstraZeneca, Aventis, AVER, Bristol-Myers Squibb Company, Cypress, Dove, Elan, Eli Lilly and Company, Forest, GlaxoSmith Kline, Hypnion, Impax, Johnson & Johnson, King, Ludbeck McNeil, MediciNova, Novartis, Orexo, Prestwick, Purdue, Resteva, Roche, Servier, Syrex, Vivometrics, Wyeth, Yamanuchi, Xenoport.

Commercial Support

Supported by an educational grant from Somaxon Pharmaceuticals, Inc.

Disclaimers
The content of this video activity may include product information that is inconsistent with or outside of the approved labeling for these products in the United States. Before prescribing any medication, you must familiarize yourself with the manufacturer's product information.

To earn continuing education credit, view this online course and complete the posttest and evaluation provided. A passing score of 75% or more must be achieved on the posttest. A link is provided within this online activity to access the posttest and evaluation. You will have the option of printing a CME Certificate for your records after submission of the evaluation.

CME LLC and Somaxon Pharmaceuticals, Inc. are not responsible for the speaker's statements, materials, acts or omissions.

Continuing Medical Education
CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Content Originally Presented: 10/30/08; 7:15-9:15pm
Online Date: 12/20/08
Credit Expiration Date: 12/20/09

This activity is based on the symposium Expanding the Armamentarium in the Treatment of Insomnia: Understanding the Pharmacology of Current and Emerging Treatments on October 30, 2008 in San Diego, CA and may not reflect the most current data. Participants who attended the live symposium mentioned above cannot claim credit for this activity.